ONC BeOne Medicines Ltd. - American Depositary Shares

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$306.04
Price · May 20, 2026
Fundamentals as of May 6, 2026
52W Range
$235–$385
47% of range
Analyst Rating
BUY
15 analysts
Price Target
$411
+34% upside
P/E (TTM)
1599.0
ROE
7.1%
Net Profit Margin
5.4%

ONC Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$306.04
Market Cap
$437.81B
P/E (TTM)
1599.0
EPS (TTM)
$0.19
Revenue (TTM)
$5.34B
Div Yield
—
ROE
7.1%
Debt/Equity
0.2
52W Range
$235 – $385

ONC Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $5.34B
10-point trend, +499248.9%
2016-12-31 → 2025-12-31
EPS $0.19
7-point trend, +115.6%
2019-12-31 → 2025-12-31
Free Cash Flow $942M
8-point trend, +933.3%
2016-12-31 → 2025-12-31
Margins 5.4%
2025-12-31 → 2025-12-31

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
ONC
Peer Median
P/E (TTM)
5-point trend, +814.1%
1599.0
—
P/S (TTM)
5-point trend, -73.6%
81.9
7.3
P/B
5-point trend, -27.3%
100.4
5.0
EV / EBITDA
5-point trend, +626.2%
737.6
—
Price / FCF
5-point trend, +394.0%
464.9
—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
ONC
Peer Median
Gross Margin
87.5%
86.0%
Operating Margin
5-point trend, +103.7%
8.4%
—
Net Profit Margin
5-point trend, +102.4%
5.4%
-0.43%
ROA
5-point trend, +108.3%
4.1%
-46.4%
ROE
5-point trend, +110.1%
7.1%
-6.6%
ROIC
5-point trend, +106.2%
5.7%
—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
ONC
Peer Median
Debt / Equity
5-point trend, +172.3%
0.2
67.1
Current Ratio
5-point trend, -9.8%
3.4
1.7
Quick Ratio
5-point trend, -12.8%
3.0
—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
ONC
Peer Median
Revenue YoY
5-point trend, +354.2%
40.2%
—
Revenue CAGR 3Y
5-point trend, +354.2%
55.7%
—
Revenue CAGR 5Y
5-point trend, +354.2%
76.8%
—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
ONC
Peer Median
EPS (Diluted)
5-point trend, +115.7%
$0.19
—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
ONC
Peer Median

ONC Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 15 analysts
  • Strong Buy 3 20.0%
  • Buy 11 73.3%
  • Hold 1 6.7%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

27 analysts · 2026-05-20
Median target $409.00 +33.6%
Mean target $411.38 +34.4%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
6.9%
Period EPS Actual EPS Est Surprise
March 31, 2026 $13.35 $0.49 12.9%
Dec. 31, 2025 $0.28 $0.63 -0.34%
Sept. 30, 2025 $0.57 $0.61 -0.03%
June 30, 2025 $0.39 $0.03 0.36%
Dec. 31, 2024 $22.65 $1.19 21.5%

Peer Comparison Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
ONC $437.81B 1599.0 40.2% 5.4% 7.1% 87.5%
ANL — — — — — —

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 17
Annual Income Statement data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Revenue 11-point trend, +60506.1% $5.34B $3.81B $2.46B $1.42B $1.18B $309M $428M $198M $238M $1M $9M
Cost of Revenue 7-point trend, +286475000.00 · · · $286M $165M $71M $71M $29M $5M $0 ·
Gross Profit 5-point trend, +362.2% $4.67B $3.22B $2.08B $1.13B $1.01B · · · · · ·
R&D Expense 11-point trend, +3583.9% $2.15B $1.95B $1.78B $1.64B $1.46B $1.29B $927M $679M $269M $98M $58M
SG&A Expense 11-point trend, +28370.6% $2.08B $1.83B $1.51B $1.28B $990M $600M $388M $195M $63M $20M $7M
Operating Expenses 11-point trend, +6348.0% $4.23B $3.78B $3.29B $2.92B $2.45B $1.97B $1.39B $904M $337M $118M $66M
Operating Income 11-point trend, +888.0% $447M $-568M $-1.21B $-1.79B $-1.44B $-1.66B $-960M $-706M $-98M $-117M $-57M
Interest Income 3-point trend, -10.0% $71M $70M $78M · · · · · · · ·
Other Non-op 11-point trend, -3576.6% $-43M $-13M $308M $-224M $16M $37M $7M $2M $12M $-972.0K $1M
Pretax Income 11-point trend, +830.0% $417M $-533M $-826M $-1.96B $-1.44B $-1.62B $-944M $-690M $-91M $-119M $-57M
Income Tax 11-point trend, +129921000.00 $130M $112M $56M $43M $19M $10M $7M $-16M $2M $54.0K $0
Net Income 11-point trend, +602.5% $287M $-645M $-882M $-2.00B $-1.46B $-1.62B $-949M $-674M $-93M $-119M $-57M
EPS (Basic) 7-point trend, +116.4% $0.20 $-0.47 $-0.65 $-1.49 $-1.21 $-1.50 $-1.22 · · · ·
EPS (Diluted) 7-point trend, +115.6% $0.19 $-0.47 $-0.65 $-1.49 $-1.21 $-1.50 $-1.22 · · · ·
Shares (Basic) 7-point trend, +81.6% 1,417,803,727 1,368,746,793 1,357,034,547 1,340,729,572 1,206,210,049 1,085,131,783 780,701,283 · · · ·
Shares (Diluted) 7-point trend, +88.9% 1,474,829,908 1,368,746,793 1,357,034,547 1,340,729,572 1,206,210,049 1,085,131,783 780,701,283 · · · ·
EBITDA 8-point trend, +603.0% $589M · · $-1.72B $-1.39B $-1.63B $-941M $-695M $-94M $-117M ·
Balance Sheet 31
Annual Balance Sheet data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Cash & Equivalents 11-point trend, +25349.3% $4.55B $2.63B $3.17B $3.87B $4.38B $1.38B $618M $713M $240M $88M $18M
Short-term Investments 8-point trend, -99.1% · · $3M $665M $2.24B $3.27B $365M $1.07B $598M $281M ·
Receivables 9-point trend, +2839.6% $865M $676M $358M $173M $483M $60M $71M $41M $29M · ·
Inventory 9-point trend, +5464.7% $608M $495M $416M $282M $243M $89M $29M $16M $11M · ·
Prepaid Expense 11-point trend, +3578.9% $213M $193M $257M $217M $270M $160M $90M $91M $36M $6M $6M
Other Current Assets 2-point trend, +132.0% · · · · $27M $12M · · · · ·
Current Assets 11-point trend, +5765.9% $6.23B $3.99B $4.20B $5.21B $7.61B $4.96B $1.17B $1.94B $913M $374M $106M
PP&E (Net) 11-point trend, +24728.8% $1.64B $1.58B $1.32B $846M $588M $358M $242M $157M $63M $26M $7M
PP&E (Gross) 9-point trend, +3980.7% $2.04B $1.32B $833M $724M $525M $345M $258M $77M $50M · ·
Accum. Depreciation 11-point trend, +8589.9% $529M $399M $249M $171M $124M $73M $37M $20M $14M $7M $6M
Goodwill Flat — no change across 6 periods · · · $109.0K $109.0K $109.0K $109.0K $109.0K $109.0K · ·
Intangibles 9-point trend, +764.9% $63M $51M $57M $41M $47M $5M $6M $7M $7M · ·
Other Non-current Assets 11-point trend, +2537.6% $102M $160M $125M $176M $163M $113M $68M $54M $43M $5M $4M
Total Assets 11-point trend, +6912.9% $8.19B $5.92B $5.81B $6.38B $8.54B $5.60B $1.61B $2.25B $1.05B $406M $117M
Accounts Payable 11-point trend, +5234.5% $479M $405M $315M $295M $262M $232M $122M $113M $70M $12M $9M
Accrued Liabilities 9-point trend, +20018.3% $1.11B $804M $694M $467M $558M $346M $164M $100M · · $6M
Short-term Debt 4-point trend, +9063000.00 $9M $852M · · · $335M $0 · · · ·
Current Liabilities 11-point trend, +5099.7% $1.83B $2.21B $1.81B $1.47B $1.60B $1.08B $310M $246M $150M $35M $35M
Capital Leases 7-point trend, +104.9% $53M $44M $22M $35M $43M $29M $26M · · · ·
Deferred Tax 9-point trend, +53209000.00 $53M $42M $16M $16M $14M $11M $11M $11M $0 · ·
Other Non-current Liabilities 11-point trend, +76323.8% $80M $67M $51M $46M $54M $57M $47M $49M $32M $564.0K $105.0K
Total Liabilities 11-point trend, +8917.3% $3.83B $2.59B $2.27B $2.00B $2.40B $1.73B $634M $496M $362M $53M $42M
Long-term Debt 9-point trend, +4434.6% $836M $1.02B $886M $538M $630M $519M $83M $50M $18M · ·
Total Debt 7-point trend, +5475.1% $1.03B · · $538M $630M $854M $83M $50M $18M · ·
Common Stock 11-point trend, +1100.0% $144.0K $138.0K $135.0K $135.0K $133.0K $118.0K $79.0K $77.0K $59.0K $52.0K $12.0K
Paid-in Capital 11-point trend, +69901.3% $12.76B $12.09B $11.60B $11.54B $11.19B $7.41B $2.93B $2.74B $1.00B $591M $18M
Retained Earnings 11-point trend, -6939.1% $-8.32B $-8.61B $-7.96B $-7.08B $-5.08B $-3.55B $-1.96B $-1.01B $-331M $-237M $-118M
AOCI 11-point trend, -4221.9% $-78M $-149M $-99M $-77M $18M $7M $-8M $2M $-480.0K $-946.0K $-2M
Stockholders' Equity 11-point trend, +4385.6% $4.36B $3.33B $3.54B $4.38B $6.13B $3.87B $962M $1.74B $670M $353M $-102M
Liabilities + Equity 11-point trend, +6912.9% $8.19B $5.92B $5.81B $6.38B $8.54B $5.60B $1.61B $2.25B $1.05B $406M $117M
Shares Outstanding 11-point trend, +1140.4% 1,441,075,618 1,387,367,704 1,359,513,224 1,356,140,180 1,334,804,281 1,190,821,941 801,340,698 776,263,184 592,072,330 515,833,609 116,174,094
Cash Flow 15
Annual Cash Flow data for ONC
Metric Trend 20252024202320222021202020192018201720162015
D&A 11-point trend, +9070.6% $142M $172M $88M $66M $46M $32M $19M $10M $5M $2M $2M
Stock-based Comp 11-point trend, +4903.0% $511M $442M $368M $303M $241M $183M $134M $87M $43M $11M $10M
Deferred Tax 10-point trend, +1332.9% $9M $26M $687.0K $3M $3M $-114.0K $-9M $-22M $-6M $-768.0K ·
Amort. of Intangibles 11-point trend, +10071000.00 $10M $5M $7M $4M $2M $846.0K $1M $894.0K $250.0K $0 $0
Other Non-cash 7-point trend, +178.4% $179M · · $134M $-131M $126M $55M $51M $64M · ·
Operating Cash Flow 11-point trend, +2930.1% $1.13B $-141M $-1.16B $-1.50B $-1.30B $-1.28B $-750M $-548M $13M $-90M $-40M
CapEx 11-point trend, +3397.2% $186M $493M $562M $325M $263M $118M $90M $70M $46M $24M $5M
Investing Cash Flow 11-point trend, -368.8% $-276M $-548M $60M $1.08B $641M $-3.17B $554M $-638M $-356M $-222M $-59M
Net Debt Issued 5-point trend, -308.4% $-36M · · $0 $0 · $-33M $-9M · · ·
Stock Issued 8-point trend, +0.00 · · $0 $0 $50M $4.23B $0 $0 $150M $0 ·
Net Stock Activity 5-point trend, +0.00 · · · $0 $50M $4.23B $0 $0 · · ·
Financing Cash Flow 11-point trend, +926.6% $1.06B $193M $416M $-19M $3.64B $5.20B $86M $1.69B $490M $381M $103M
Net Change in Cash 11-point trend, +49532.3% $1.97B $-547M $-689M $-508M $2.99B $769M $-120M $501M $152M $70M $4M
Taxes Paid 10-point trend, +402624.0% $101M $69M $56M $30M $16M $11M $9M $12M $29M $25.0K ·
Free Cash Flow 8-point trend, +933.3% $942M · · $-1.82B $-1.56B $-1.40B $-840M $-618M $-34M $-113M ·
Profitability 8
Annual Profitability data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Gross Margin 87.5% · · · · · · · · · ·
Operating Margin 8-point trend, +100.1% 8.4% · · -126.4% -122.3% -536.7% -224.2% -356.1% -41.3% -10940.2% ·
Net Margin 8-point trend, +100.0% 5.4% · · -141.5% -120.2% -517.0% -221.5% -339.9% -39.1% -11141.8% ·
Pretax Margin 8-point trend, +100.1% 7.8% · · -138.5% -122.3% -523.9% -220.3% -348.0% -38.2% -11136.7% ·
EBITDA Margin 8-point trend, +100.1% 11.0% · · -121.7% -118.4% -526.4% -219.8% -350.8% -39.3% -10940.2% ·
ROA 8-point trend, +108.9% 4.1% · · -26.9% -19.8% -44.3% -49.1% -40.9% -12.8% -45.6% ·
ROE 8-point trend, +107.4% 7.1% · · -44.3% -27.6% -66.1% -70.2% -55.9% -18.2% -94.9% ·
ROIC 8-point trend, +117.2% 5.7% · · -37.2% -20.6% -34.7% -92.5% -38.6% -14.7% -33.2% ·
Liquidity & Solvency 4
Annual Liquidity & Solvency data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Current Ratio 8-point trend, -68.1% 3.4 · · 3.5 4.8 4.6 3.8 7.9 6.1 10.7 ·
Quick Ratio 8-point trend, +18.6% 3.0 · · 3.2 4.4 4.4 3.4 7.4 5.8 2.5 ·
Debt / Equity 7-point trend, +757.5% 0.2 · · 0.1 0.1 0.2 0.1 0.0 0.0 · ·
LT Debt / Equity 7-point trend, +1498.6% 0.2 · · 0.0 0.0 0.0 0.1 0.0 0.0 · ·
Efficiency 3
Annual Efficiency data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Asset Turnover 8-point trend, +18373.2% 0.8 · · 0.2 0.2 0.1 0.2 0.1 0.3 0.0 ·
Inventory Turnover 6-point trend, +19.9% · · · 1.1 1.0 1.2 3.2 2.1 0.9 · ·
Receivables Turnover 7-point trend, -57.2% 6.9 · · 4.3 4.3 4.7 7.7 5.6 16.2 · ·
Per Share 5
Annual Per Share data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Book Value / Share 8-point trend, +342.4% $3.03 · · $3.23 $4.68 $3.25 $1.20 $2.24 $1.13 $0.68 ·
Revenue / Share 3-point trend, +271.5% $3.62 · · $1.06 $0.98 · · · · · ·
Cash Flow / Share 3-point trend, +171.0% $0.76 · · $-1.12 $-1.08 · · · · · ·
Cash / Share 8-point trend, +1759.5% $3.16 · · $2.85 $3.28 $1.16 $0.77 $0.92 $0.40 $0.17 ·
EPS (TTM) 8-point trend, +200.0% $0.19 $-0.47 $-0.65 $-1.49 $-1.21 $-1.50 $-1.22 · $-0.19 · ·
Growth Rates 3
Annual Growth Rates data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Revenue YoY 5-point trend, -85.7% 40.2% 55.0% 73.7% 20.4% 280.8% · · · · · ·
Revenue CAGR 3Y 3-point trend, -44.1% 55.7% 48.0% 99.7% · · · · · · · ·
Revenue CAGR 5Y 76.8% · · · · · · · · · ·
Valuation (TTM) 14
Annual Valuation (TTM) data for ONC
Metric Trend 20252024202320222021202020192018201720162015
Revenue TTM 11-point trend, +60506.1% $5.34B $3.81B $2.46B $1.42B $1.18B $309M $428M $198M $238M $1M $9M
Net Income TTM 11-point trend, +602.5% $287M $-645M $-882M $-2.00B $-1.46B $-1.62B $-949M $-674M $-93M $-119M $-57M
Market Cap 8-point trend, +2695.6% $437.81B · · $298.27B $361.64B $307.70B $132.83B $108.88B $57.86B $15.66B ·
Enterprise Value 7-point trend, +661.4% $434.29B · · $294.27B $355.65B $303.90B $131.93B $107.15B $57.04B · ·
P/E 8-point trend, +410.9% 1599.0 -393.0 -277.5 -147.6 -223.9 -172.3 -135.9 · -514.3 · ·
P/S 8-point trend, -99.4% 81.9 · · 210.7 307.4 996.2 310.2 549.3 242.7 14636.2 ·
P/B 8-point trend, +126.2% 100.4 · · 68.0 57.9 79.5 138.0 62.6 86.4 44.4 ·
P / Tangible Book 6-point trend, +27.9% 101.9 78.1 70.5 68.7 59.4 79.6 · · · · ·
P / Cash Flow 8-point trend, +321.9% 388.3 · · -199.3 -278.5 -239.7 -177.0 -198.8 4537.1 -175.0 ·
P / FCF 8-point trend, +435.5% 464.9 · · -163.7 -231.6 -219.6 -158.2 -176.2 -1720.8 -138.6 ·
EV / EBITDA 7-point trend, +221.2% 737.6 · · -170.8 -255.4 -186.9 -140.2 -154.1 -608.7 · ·
EV / FCF 7-point trend, +127.2% 461.2 · · -161.5 -227.7 -216.9 -157.1 -173.4 -1696.5 · ·
EV / Revenue 7-point trend, -66.0% 81.3 · · 207.8 302.4 983.9 308.1 540.5 239.3 · ·
Earnings Yield 8-point trend, +131.6% 0.06% -0.25% -0.36% -0.68% -0.45% -0.58% -0.74% · -0.19% · ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $5.34B$3.81B$2.46B$1.42B$1.18B
Gross Margin % 87.5%————
Operating Margin % 8.4%——-126.4%-122.3%
Net Income $287M$-645M$-882M$-2.00B$-1.46B
Diluted EPS $0.19$-0.47$-0.65$-1.49$-1.21
Balance Sheet
2025-12-312024-12-312023-12-312022-12-312021-12-31
Debt / Equity 0.2——0.10.1
Current Ratio 3.4——3.54.8
Quick Ratio 3.0——3.24.4
Cash Flow
2025-12-312024-12-312023-12-312022-12-312021-12-31
Free Cash Flow $942M——$-1.82B$-1.56B

ONC AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Grok NEUTRAL 0.75
↑ Bullish

I see BeOne Medicines turning the corner toward profitability, with elite gross margins and shrinking losses that could ignite a breakout if pipeline news hits right. Gross margins sit firm at 86%. That reflects commanding pricing power on their specialty drugs, far above commodity pharma levels. Net margins have tightened to just -0.43%. They're nearly cash-flow positive on operations, a huge leap from -10.6% last quarter. EPS losses halved to -0.20. Combine that with Wolfe Research's Outperform initiation on April 4, and my read is multi-bagger potential by 2026Q2.

↓ Bearish

BeOne remains a money-losing biotech at lofty valuations, vulnerable to trial failures that could crater the stock overnight. ROE lingers negative at -6.58%. Equity is eroding with no returns for shareholders yet. P/S trades at 7.3 times despite zero profits. That's betting heavily on unproven growth in a sector full of flameouts. Market cap has slipped to $261 million. Recent price volatility around $250 shows fading conviction amid high volumes.

Claude NEUTRAL 0.42
↑ Bullish

BeOne has the gross margins of a software company — 86% — which suggests either a breakthrough therapeutic or a rare licensing model that commands pricing power. Wolfe Research's recent Outperform initiation signals institutional conviction that the market hasn't priced in the upside yet. The stock has stabilized around $245 after volatility, and at 7.3x sales, it's cheaper than it was a quarter ago, which means either the market is being rational about near-term losses or it's capitulating before a catalyst.

↓ Bearish

This company is burning cash and has never turned a profit — negative 43 basis points net margin and negative 6.6% ROE tell me the 86% gross margin is being obliterated by operating expenses. The debt-to-equity ratio of 27.4x is alarming; that's not a balance sheet, that's a leverage bomb. Market cap has fallen 5% in one quarter while the stock whipsaws 25% week-to-week, suggesting institutional holders are quietly exiting before the next earnings miss.

Gemini NEUTRAL 0.60
↑ Bullish

BeOne Medicines is effectively cleaning up its balance sheet while maintaining the high-margin profile essential for biotech success. The company boasts an 85.99% gross margin, which indicates that their underlying drug development pipeline commands serious pricing power should they reach commercial scale. Furthermore, the debt-to-equity ratio has improved to 27.38, showing management is successfully deleveraging the firm. This reduction in financial risk is vital for a company that is still working toward consistent profitability, as it provides the necessary runway to navigate the expensive clinical trial process without immediate dilution concerns.

↓ Bearish

The fundamental reality remains that BeOne is still burning cash and failing to generate a positive return for its shareholders. The company posted a -6.58% return on equity, which confirms that they are currently destroying shareholder value rather than creating it through their operations. Additionally, the stock trades at a 7.3173 price-to-sales multiple, a valuation that is difficult to justify for a business that has yet to prove it can turn a net profit. Investors are essentially paying a premium for a future promise that remains unproven in the current quarterly data.

Chatgpt NEUTRAL 0.60
↑ Bullish

I think the strongest bullish case rests on durable margins, a healthy balance sheet, and credible upside catalysts. Gross margin TTM is 85.99%. That implies pricing power and cost discipline that can bankroll R&D without destroying profits when growth hits scale. Debt/Equity stands at 27.38%. It's modest leverage that preserves financial flexibility to fund pipeline progress. Wolfe Research initiated coverage with an Outperform rating in April 2026. That external validation can lift sentiment and attract capital if execution meets expectations.

↓ Bearish

My bear case is that profitability remains elusive and the stock trades on hype rather than proven growth. Net margin TTM is -0.43%. This shows the business is not yet generating real operating profit, even with strong margins. EPS TTM: -0.20 per share. Negative earnings per share reflect ongoing losses that equity holders must fund. P/S (TTM) 7.3173. The valuation looks rich given negative earnings and limited near-term profitability.

Round 2 — Responses & Rebuttals

Grok

Claude, calling the debt-to-equity ratio a leverage bomb ignores the clear deleveraging that's buying BeOne time to hit profitability milestones. It's improved to 27.38 from 31.7 last quarter, materially reducing balance sheet risk without tapping equity markets. Pair that with a current ratio of 1.94, and liquidity comfortably covers near-term obligations — this isn't a bomb, it's a controlled burn fueling growth.

Claude

I need to push back on Grok here. You're calling net margin improvement from -10.6% to -0.43% a 'huge leap' toward profitability, but that's reading the trend wrong. A company still losing money on every dollar of sales isn't nearly cash-flow positive — it's still cash-flow negative. The real issue is that gross margin of 86% is being crushed by operating expenses, which means R&D and SG&A are eating 87 cents of every sales dollar. That's not a turnaround story; that's a company betting its entire future on volume scaling before the cash runs out. Wolfe's Outperform call is a catalyst signal, not validation that losses are shrinking fast enough to matter.

Gemini

Grok, I think your optimism regarding the path to profitability is premature. You cited the net margin of -0.43% as evidence they are nearly cash-flow positive, but that figure ignores the massive capital expenditure required to sustain a biotech pipeline. A debt-to-equity ratio of 27.38 means the company is heavily reliant on debt to bridge that gap. This level of leverage creates a structural vulnerability where any delay in clinical trials could force a dilutive equity raise, effectively wiping out the upside potential you are projecting for 2026Q2.

Chatgpt

Claude, your point about software-like margins overstates the story. Gross margin around 86% shows pricing power on BeOne's offerings, but it doesn't prove profitability because operating costs and R&D still burn cash. Wolfe's Outperform initiation could lift sentiment, yet the risk remains that the stock runs on hype if pipeline progress stalls. That said, the company still faces meaningful R&D timelines and potentially dilutive financing needs if cash burn persists.

Round 3 — Final Rebuttals

G
Grok

Gemini and Claude, your debt concerns miss how the chart is screaming accumulation ahead of catalysts. BeOne hit a capitulation low on June 27, 2025, closing at $241.2 on 2 million shares volume — triple the recent average — flushing weak hands. It's since based up to $250 with volume drying to 1.3 million, a textbook setup for institutional positioning into 2026Q2 pipeline readouts. This trumps balance sheet noise if Wolfe's growth thesis plays out.

C
Claude

I need to call out something Grok said that nobody pushed back on: that debt-to-equity improved from 31.7 to 27.4. That's true numerically, but Grok framed it as 'materially reducing balance sheet risk' — and I disagree with the implication. A D/E of 27.4 is still structurally unsustainable for a cash-burning biotech. The improvement quarter-over-quarter matters only if it's part of a clear path to sub-5x leverage within 18 months. Without knowing BeOne's debt maturity schedule and burn rate, calling a 13% quarterly improvement a 'controlled burn' is wishful reading. Grok, what's the actual debt maturity wall here, and how many quarters of current burn does the cash balance cover?

G
Gemini ⇄ Mind changed

Grok, I am revising my take on the debt situation because you are right about the current ratio. At 1.94, the company has nearly two dollars in liquid assets for every dollar of short-term liability, which provides a genuine cushion that I previously underestimated. However, I disagree with your thesis that this is a 'controlled burn' because the broader macro environment is shifting. We are entering a higher-for-longer interest rate regime that makes servicing a 27.38 debt-to-equity ratio increasingly expensive. This leverage, while improving, remains a significant drag on future earnings potential as borrowing costs rise.

C
Chatgpt

Grok, I disagree with your view that BeOne is a multi-bagger by 2026Q2. Net margin TTM is -0.43% — that means BeOne isn't profitable on current sales, and at a roughly $261 million market cap the upside will depend on a timely, material pipeline milestone, a favorable licensing deal, or stronger commercialization momentum to justify the optimism rather than any immediate operating leverage or cost discipline, since profitability remains contingent on trial readouts, regulatory timing, and potential funding moves if milestones slip.

Price Forecasts

Model 3M Target 6M Target Reasoning
G Grok 3M Target $310.00 6M Target $450.00 Reasoning I think BeOne is set for a re-rating as shrinking losses meet pipeline catalysts, lifting shares well above current levels into 2026Q2. My key catalyst is the Q2 2026 earnings print around late July 2026, where net margins could flip positive on sales scaling from high-margin drugs. The biggest risk is a clinical trial readout flop before then, triggering a funding raise and dilution. Current P/S at 7.3x is a bargain for 86% gross margins, meaning the market pays little for elite pricing power despite near-breakeven ops — that alone supports 25% upside if trends hold.
C Claude 3M Target — 6M Target — Reasoning BeOne is a binary-outcome biotech where the next 6 months hinge entirely on pipeline readouts, not balance sheet repair. My thesis: the stock reprices on clinical trial results, not operational deleveraging. The concrete catalyst is a Phase 3 readout or regulatory milestone that either validates Wolfe's Outperform thesis or invalidates it — I cannot forecast which without trial data. The concrete risk is a missed timeline or failed trial that forces dilutive financing, given the 27.4x D/E ratio leaves zero margin for error. At 7.3x sales with negative earnings, valuation is hostage to binary news. Without visibility into trial timing or probability of success, I cannot anchor a price target to anything but noise. Grok's technical setup and Wolfe's initiation are sentiment signals, not fundamentals. I hold my 0.42 confidence and return null.
G Gemini 3M Target $265.00 6M Target $290.00 Reasoning My thesis is that BeOne’s high gross margins will finally translate into market confidence once the company proves it can stabilize its cash burn. A specific catalyst for the six-month target is the next quarterly earnings report, where a move to positive net income would validate the current valuation. The primary risk is a failed Phase 3 trial readout, which would immediately destroy the company's growth narrative. The current P/S ratio of 7.3 means investors are paying over seven dollars for every dollar of revenue, a premium that requires consistent, high-growth execution to justify. While I remain cautious about their debt, the current liquidity cushion provides enough runway to avoid immediate dilution.
C Chatgpt 3M Target $270.00 6M Target $310.00 Reasoning I think BeOne has a credible path to profitability if catalysts land, but upside hinges on a big pipeline milestone and favorable financing terms. Catalyst: a 2026Q2 earnings release with meaningful pipeline readouts and the Wolfe Research Outperform initiation that could lift sentiment. Risk: a clinical setback or dilutive financing could derail the rally and re-pricing. BeOne trades around $245 and P/S near 7.3x. That multiple means investors are paying for future growth rather than current profits, so outcomes hinge on real milestones rather than today's losses.

Latest News Recent headlines mentioning this company

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.